Filter by
News (75)
RSS
Global Health EDCTP3 has received 277 applications by the 4 March 2026 first stage deadline for four topics of the 2026 calls. Successful consortia will be invited to submit a full proposal for the second stage by 17 September 2026.
From malaria and HIV to pandemic preparedness and regulatory science, meet the EDCTP-funded scientists and leaders advancing research, strengthening health systems and building scientific capacity across Africa.
Results from the EDCTP2-funded Phase IIb trial demonstrate that the oral vaccine ETVAX significantly reduces moderate-to-severe diarrhoea in young children caused by E. coli.
Through collaboration with European health bodies, Global Health EDCTP3 aims to strengthen tuberculosis prevention and treatment, especially involving children and people with weakened immune systems.
The new Acoziborole Winthrop, supported by EDCTP, will help treat human African trypanosomiasis (HAT), commonly known as sleeping sickness.
The Global Health EDCTP3 Governing Board has appointed new members to its Stakeholders' Group, following an evaluation of 70 applications received from organisations worldwide. 32 African, European and international organisations have been appointed as members and three as observers.
Dr Delese Mimi Darko, inaugural Director General of the African Medicines Agency and a former EDCTP grant holder, reflects on building strong regulatory systems to advance safe and equitable access to medicines across the continent and on the role of women in shaping public health.
The opening ceremony of the EDCTP Forum 2027 will take place on 5 April and will be followed by four days of scientific programme from 6 to 9 April 2027. These will include plenary sessions, parallel sessions, prize-giving ceremonies, an exhibition of posters, scientific symposia, workshops, etc.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion for Acoziborole Winthrop, a single-dose oral treatment against sleeping sickness.
The STOP2030 project, co-funded by Global Health EDCTP3, secures national approval for the ivermectin-albendazole fixed-dose combination, a single-pill treatment effective against all major soil-transmitted helminths.